Abstract
* Akynzeo, a combination of two drugs (netupitant and palonosetron), has been approved to prevent nausea and vomiting in patients undergoing cancer chemotherapy.
* The most common adverse effects are headache, asthenia, dyspepsia, fatigue, constipation, and erythema. Patients should be monitored for symptoms of serotonin syndrome.